ArticleTherapeutic advances in medical oncology2020

Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis.

Satoshi Ikeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.